fluoxetine has been researched along with Nervous System Disorders in 18 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China." | 9.22 | Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. ( Cai, Z; Guo, Y; He, Y; Jiang, X; Ma, K; Tang, B; Zeng, S; Zhang, Y, 2016) |
| "To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China." | 5.22 | Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. ( Cai, Z; Guo, Y; He, Y; Jiang, X; Ma, K; Tang, B; Zeng, S; Zhang, Y, 2016) |
| " We differentiated and treated human SK-N-SH neuroblastoma cells with a mixture (fluoxetine, carbamazepine and venlafaxine) and valproate (used as a positive control to induce autism-associated profiles), followed by transcriptome analysis with RNA-Seq approach." | 3.83 | Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders. ( Kaushik, G; Thomas, MA; Xia, Y; Yang, L, 2016) |
| "The side effect profile and safety of fluoxetine are reviewed." | 3.75 | The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Depression has a female sex predilection with 2 to 3% of the pregnant women population presently requiring treatment with selective serotonin reuptake inhibitors (SSRI)." | 2.44 | Fetal and neonatal effects of maternal drug treatment for depression. ( Belik, J, 2008) |
| "Fluoxetine was reported to improve neurological manifestations in patients with Alzheimer's disease, stroke, Huntington's disease, multiple sclerosis, traumatic brain injury, and epilepsy." | 2.44 | Therapeutic potential of fluoxetine in neurological disorders. ( De Keyser, J; Heerings, M; Heersema, DJ; Koch, MW; Mostert, JP, 2008) |
| "A majority of cases of idiopathic autism in children likely result from unknown environmental triggers in genetically susceptible individuals." | 1.46 | Dysregulation of autism-associated synaptic proteins by psychoactive pharmaceuticals at environmental concentrations. ( Kaushik, G; Pfau, JC; Thomas, MA; Xia, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, N | 1 |
| Qin, W | 1 |
| Tian, S | 1 |
| Xu, Q | 1 |
| Wold, EA | 1 |
| Zhou, J | 1 |
| Zhen, XC | 1 |
| Kaushik, G | 2 |
| Xia, Y | 2 |
| Pfau, JC | 1 |
| Thomas, MA | 2 |
| Blatteau, JE | 1 |
| de Maistre, S | 1 |
| Lambrechts, K | 1 |
| Abraini, J | 1 |
| Risso, JJ | 1 |
| Vallée, N | 1 |
| Guo, Y | 1 |
| He, Y | 1 |
| Tang, B | 1 |
| Ma, K | 1 |
| Cai, Z | 1 |
| Zeng, S | 1 |
| Zhang, Y | 1 |
| Jiang, X | 1 |
| Yang, L | 1 |
| Belik, J | 1 |
| Moha ou Maati, H | 1 |
| Peyronnet, R | 1 |
| Devader, C | 1 |
| Veyssiere, J | 1 |
| Labbal, F | 1 |
| Gandin, C | 1 |
| Mazella, J | 1 |
| Heurteaux, C | 1 |
| Borsotto, M | 1 |
| Mead, GE | 1 |
| Hsieh, CF | 1 |
| Lee, R | 1 |
| Kutlubaev, MA | 1 |
| Claxton, A | 1 |
| Hankey, GJ | 1 |
| Hackett, ML | 1 |
| Mostert, JP | 1 |
| Koch, MW | 1 |
| Heerings, M | 1 |
| Heersema, DJ | 1 |
| De Keyser, J | 1 |
| Dave, V | 1 |
| Mullaney, KJ | 1 |
| Goderie, S | 1 |
| Kimelberg, HK | 1 |
| Aschner, M | 1 |
| Hotaling, AJ | 1 |
| Park, AH | 1 |
| Chow, JM | 1 |
| Ivanusa, Z | 1 |
| Hećimović, H | 1 |
| Demarin, V | 1 |
| Virden, TB | 1 |
| Baker, LE | 1 |
| Measom, MO | 1 |
| Jalil, P | 1 |
| Austin, LS | 1 |
| Arana, GW | 1 |
| Melvin, JA | 1 |
| Wernicke, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluoxetine and Nervous System Disorders
| Article | Year |
|---|---|
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
Topics: Allosteric Regulation; Clinical Trials as Topic; Humans; Ligands; Nervous System Diseases; Piperidin | 2020 |
Fetal and neonatal effects of maternal drug treatment for depression.
Topics: Animals; Depression; Female; Fetal Diseases; Fluoxetine; Gastrointestinal Diseases; Humans; Hyperten | 2008 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Therapeutic potential of fluoxetine in neurological disorders.
Topics: Animals; Brain Chemistry; Fluoxetine; Humans; Nervous System Diseases; Selective Serotonin Reuptake | 2008 |
Serotonin syndrome.
Topics: Fluoxetine; Humans; Monoamine Oxidase Inhibitors; Nervous System Diseases; Receptors, Serotonin; Ser | 1997 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
2 trials available for fluoxetine and Nervous System Disorders
| Article | Year |
|---|---|
Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; China; Double-Blind Meth | 2016 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
11 other studies available for fluoxetine and Nervous System Disorders
| Article | Year |
|---|---|
Dysregulation of autism-associated synaptic proteins by psychoactive pharmaceuticals at environmental concentrations.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Carbamazepine; Environment; Female; Flu | 2017 |
Fluoxetine stimulates anti-inflammatory IL-10 cytokine production and attenuates sensory deficits in a rat model of decompression sickness.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Decompression Sickness; Fluoxet | 2015 |
Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders.
Topics: Animals; Autistic Disorder; Carbamazepine; Cell Line, Tumor; Environmental Pollutants; Fluoxetine; G | 2016 |
A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases.
Topics: Cell Hypoxia; Drug Discovery; Drug Evaluation, Preclinical; Fatty Acids, Unsaturated; Fluoxetine; Gr | 2011 |
Astrocytes as mediators of methylmercury neurotoxicity: effects on D-aspartate and serotonin uptake.
Topics: Animals; Animals, Newborn; Aspartic Acid; Astrocytes; Autoradiography; Cells, Cultured; Fluoxetine; | 1994 |
A case of intractable sneezing: 'a pleasure sent from God?'.
Topics: Adolescent; Fluoxetine; Humans; Male; Nervous System Diseases; Psychotherapy; Sneezing | 1994 |
Disruption of the discriminative stimulus effects of S(+)-3,4-methylenedioxymethamphetamine (MDMA) by (+/-)-MDMA neurotoxicity: protection by fluoxetine.
Topics: Animals; Brain Chemistry; Discrimination, Psychological; Dose-Response Relationship, Drug; Fluoxetin | 1999 |
Penile anesthesia and fluoxetine.
Topics: Depressive Disorder; Fluoxetine; Humans; Male; Middle Aged; Nervous System Diseases; Penile Diseases | 1992 |
Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Drug Therapy, Combination; Epilepsy; Female; Fluoxetin | 1992 |
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients.
Topics: Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Drug Interactions; Drug Thera | 1990 |
Fluoxetine (Prozac) revisited.
Topics: Arousal; Depression; Drug Interactions; Fluoxetine; Humans; Nervous System Diseases | 1990 |